Literature DB >> 25246114

Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.

Ali Sami Gurbuz1, Funda Gode2, Necati Ozcimen3, Ahmet Zeki Isik2.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is the most serious iatrogenic complication of IVF cycles. Although the development of effective treatment strategies for this syndrome is important, preventing OHSS is more crucial. Triggering ovulation with a gonadotrophin-releasing hormone (GnRH) agonist is one method used to avoid OHSS. In this paper, three patients who developed severe OHSS after undergoing GnRH agonist triggering and freezing of all embryos in a GnRH antagonist protocol are described. A review of the literature is also provided. This report highlights the ongoing risk of severe OHSS even after GnRH agonist triggering combined with freezing all embryos in GnRH antagonist cycles. Other prevention strategies might be considered for extreme hyper-responders.
Copyright © 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GnRH agonist; OHSS; freeze-all; segmentation; trigger

Mesh:

Substances:

Year:  2014        PMID: 25246114     DOI: 10.1016/j.rbmo.2014.07.022

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  27 in total

1.  Does freeze all policy eliminate OHSS??? "It ain't necessarily so…".

Authors:  Zeev Blumenfeld
Journal:  J Assist Reprod Genet       Date:  2015-09-07       Impact factor: 3.412

2.  What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study.

Authors:  Theoni B Tarlatzi; Christos A Venetis; Fabienne Devreker; Yvon Englert; Anne Delbaere
Journal:  J Assist Reprod Genet       Date:  2017-07-14       Impact factor: 3.412

3.  A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.

Authors:  Yanett Anaya; Douglas A Mata; Joseph Letourneau; Hakan Cakmak; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2017-10-30       Impact factor: 3.412

Review 4.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

5.  Why more is less and less is more when it comes to ovarian stimulation.

Authors:  Zeev Blumenfeld
Journal:  J Assist Reprod Genet       Date:  2015-10-19       Impact factor: 3.412

Review 6.  The state of "freeze-for-all" in human ARTs.

Authors:  Natalia Basile; Juan A Garcia-Velasco
Journal:  J Assist Reprod Genet       Date:  2016-09-14       Impact factor: 3.412

7.  Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.

Authors:  Samuel Santos-Ribeiro; Nikolaos P Polyzos; Katrien Stouffs; Michel De Vos; Sara Seneca; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2015-05-17       Impact factor: 3.412

8.  Rare genetic variants potentially involved in ovarian hyperstimulation syndrome.

Authors:  Katrien Stouffs; Sari Daelemans; Samuel Santos-Ribeiro; Sara Seneca; Alexander Gheldof; Ali Sami Gürbüz; Michel De Vos; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2018-11-27       Impact factor: 3.412

9.  Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS.

Authors:  D Fischer; C Reisenbüchler; S Rösner; J Haussmann; P Wimberger; M Goeckenjan
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-06       Impact factor: 2.915

10.  An update on the prevention of ovarian hyperstimulation syndrome.

Authors:  Omar El Tokhy; Julia Kopeika; Tarek El-Toukhy
Journal:  Womens Health (Lond)       Date:  2016-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.